

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**

**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6606)**

**(I) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;  
(II) CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE;  
(III) COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES; AND  
(IV) CONTINUED SUSPENSION OF TRADING**

This announcement is made pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE**

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of New Horizon Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Wang Yang (“**Dr. Wang**”) has been appointed as an independent non-executive Director and a member of the audit committee (the “**Audit Committee**”) of the Board with effect from March 10, 2025.

The biographical details of Dr. Wang are as follows:

**Dr. Wang Yang** (王洋), aged 45, graduated from Wuhan University (武漢大學) with his PhD degree in accounting in July 2008, after which he served as a postdoctoral researcher at Shenzhen Stock Exchange till October 2011. Dr. Wang has been serving as the founding partner and head of compliance and risk control of Beijing Zhiming Haojin Investment Management Co., Ltd. (北京智明浩金投資管理有限公司) since January 2018 and is currently the independent non-executive director of Zhejiang NHU Company Ltd. (浙江新和成股份有限公司) (Stock Code: 002001.SZ) and INTCO MEDICAL Technology Co., Ltd. (英科醫療

科技股份有限公司) (Stock Code: 300677.SZ). He served as the director of Shenzhen Stock Exchange Zhongguancun Innovation and Entrepreneurship Enterprise Listing Incubation Base (深圳證券交易所中關村創新創業企業上市培育基地) from July 2014 to August 2017, and the senior manager of Beijing Stock Exchange (National Equities Exchange and Quotations) from May 2013 to July 2014. From September 2009 to May 2013, he served as the senior manager at Beijing working group of Shenzhen Stock Exchange and ChiNext Issuance Regulation Department of China Securities Regulatory Commission. From July 2008 to September 2009, he took the position of senior manager at Investment Banking Department of Ping An Securities.

Dr. Wang has entered into an appointment letter as an independent non-executive Director with the Company for an initial term of three years with effect from March 10, 2025, and will hold office only until the first annual general meeting of the Company after his appointment and shall then be subject to re-election at such annual general meeting in accordance with the articles of association of the Company. As specified in the appointment letter, the remuneration for Dr. Wang is USD43,600 per year, which was determined by the Board based on the recommendation of the remuneration committee of the Board (the “**Remuneration Committee**”) and with reference to the duties and responsibilities of Dr. Wang in the Company, his qualification and experience, the prevailing market rate and the remuneration policy of the Company. Such remuneration is subject to review by the Remuneration Committee and the Board from time to time.

Save as disclosed above, as at the date of this announcement, Dr. Wang (i) does not hold any position in the Company or other members of the Group; (ii) does not have any other major appointments or professional qualifications; (iii) does not, nor did he hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iv) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as respectively defined in the Listing Rules) of the Company; and (v) does not have any interest in the shares, underlying shares and debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Wang has confirmed that (i) he has satisfied all the criteria for independence as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

As at the date of this announcement, save as disclosed above, to the best knowledge of the Board, there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules (particularly in relation to sub-paragraphs (h) to (v) therein), nor are there any other matters that need to be brought to the attention of the shareholders of the Company and the Stock Exchange relating to the appointment of Dr. Wang.

The Board would like to take this opportunity to extend its warmest welcome to Dr. Wang in joining the Board.

### **COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES**

Following the appointment of Dr. Wang as an independent non-executive Director and the change in composition of the Audit Committee with effect from March 10, 2025, the Audit Committee comprises three members, two of whom are independent non-executive Directors. Accordingly, the Company is in compliance with the requirements under Rule 3.21 of the Listing Rules.

### **CONTINUED SUSPENSION OF TRADING**

Trading in the Company's shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended pending fulfilment of the Resumption Guidance (as defined in the announcement of the Company dated January 9, 2025).

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**New Horizon Health Limited**  
**Mr. Naxin YAO**  
*Chairman*

Hong Kong, March 9, 2025

*As at the date of this announcement, the Board comprises Mr. Naxin YAO as the Chairman and non-executive Director, Dr. Yiyou CHEN as executive Director and Mr. Danke YU, Mr. LAU Ngai Kee Ricky, Ms. NG Weng Sin, Ms. Jiangnan KONG and Dr. Yang WANG as independent non-executive Directors.*